Kryxana Film Coated Tablet 200mg

Indications

• Locally advanced or metastatic breast cancer (specialist use only)
• Hormone receptor-positive, HER2-negative advanced breast cancer
• Combination with fulvestrant for hormone receptor-positive advanced breast cancer after endocrine therapy
• Combination with aromatase inhibitors for postmenopausal women with advanced breast cancer as initial endocrine-based therapy

Dosage

Adults: 600 mg once daily for 21 consecutive days, followed by a 7-day break, to be repeated in 28-day cycles. It should be taken at approximately the same time each day, preferably in the morning.

Mechanism of action

Ribociclib selectively inhibits cyclin-dependent kinases 4 and 6. These kinases, when activated by binding to D-cyclins, facilitate cell cycle progression and proliferation. By inhibiting CDK4/6, ribociclib decreases the phosphorylation of the retinoblastoma protein (pRb), leading to cell cycle arrest in the G1 phase and reduced tumor cell proliferation, particularly in breast cancer models.

Pharmacodynamics

Ribociclib causes concentration-dependent changes in the QTcF interval, necessitating caution in patients taking other QTc-prolonging medications or those with a predisposition to Torsades de Pointes (TdP). Its effects on cell cycle regulation contribute to its therapeutic use in treating certain malignancies, specifically breast cancer.

Pharmacokinetics

Ribociclib is absorbed orally, with peak plasma concentrations typically occurring within 4 to 6 hours post-dose. It is extensively metabolized in the liver, primarily by cytochrome P450 enzymes, with a half-life allowing for once-daily dosing. The pharmacokinetics of ribociclib can be significantly affected by concomitant medications that either induce or inhibit these metabolic pathways.

Contra-indications

• Pre-existing QTc prolongation risk
• Concomitant use of drugs known to prolong QTc interval

Adverse effects

• Alopecia
• Anaemia
• Decreased appetite
• Asthenia
• Back pain
• Constipation
• Cough
• Decreased leucocytes
• Diarrhoea
• Dizziness
• Dry eye
• Dry mouth
• Dyspnoea
• Electrolyte imbalance
• Excessive tearing
• Fever
• Gastrointestinal discomfort
• Headache
• Hepatic disorders
• Increased risk of infection

Interactions

• Ribociclib + alfuzosin: Severe (increases exposure)
• Ribociclib + amiodarone: Severe (increases exposure)
• Ribociclib + quetiapine: Severe (increases exposure)
• Ribociclib + ergotamine: Severe (increases exposure)
• Grapefruit juice + ribociclib: Severe (increases exposure)
• Mitotane + ribociclib: Severe (decreases exposure)
• Ribociclib + pimozide: Severe (increases exposure)
• Ribociclib + alpha blockers: Severe (increases exposure)
• Ribociclib + antiarrhythmics: Severe (increases exposure)
• Ribociclib + second-generation antipsychotics: Severe (increases exposure)

Precautions

• Monitor ECG before initiating treatment, especially in patients with QTcF values <450 milliseconds
• Repeat ECG at approximately day 14 of the first cycle and at the beginning of the second cycle
• Monitor serum electrolytes (potassium, calcium, phosphorus, magnesium) before initiating treatment and periodically during treatment
• Correct any electrolyte abnormalities before starting treatment
• Assess for pulmonary symptoms indicative of interstitial lung disease and pneumonitis

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Ribociclib should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

Dosage

Children: Refer to specific drug formulations and clinical guidelines for pediatric dosage information, as it varies based on the active ingredient.

Adults: Refer to specific drug formulations and clinical guidelines for dosage information, as it varies based on the active ingredient.

Mechanism of action

The mechanism of action of anhydrous drugs typically relates to the specific active ingredient being delivered in the anhydrous form. For example, anhydrous forms of certain medications may dissolve more easily in the gastrointestinal tract, leading to increased absorption and enhanced therapeutic effects compared to their hydrated counterparts.

Pharmacodynamics

Pharmacodynamics of anhydrous forms largely depend on the drug's active ingredient. Generally, anhydrous formulations can lead to quicker onset of action due to improved solubility and absorption. The absence of water may also prevent hydrolysis of the drug, maintaining its potency and efficacy over time.

Pharmacokinetics

Pharmacokinetics of anhydrous drug forms also hinge on the specific active ingredient. Commonly, anhydrous medications may exhibit altered absorption rates due to their enhanced solubility. Distribution, metabolism, and excretion rates will vary according to the chemical properties of the drug, but anhydrous forms may allow for more predictable pharmacokinetic profiles due to their stability.

Pregnancy

The use of anhydrous substances during pregnancy should be approached with caution, and potential risks should be weighed against benefits.

Breast-feeding

It is advisable to consult healthcare providers regarding the use of anhydrous compounds while breastfeeding.

Storage

Anhydrous substances should be stored in a cool, dry place away from moisture and incompatible substances.

Indications

• Gastroesophageal reflux disease (GERD)
• Peptic ulcer disease
• Allergic rhinitis
• Anxiety
• Motion sickness

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines.

Adults: Refer to specific drug monographs for dosing information, as it varies by drug and condition.

Mechanism of action

Basic drugs often work by neutralizing stomach acid, blocking histamine receptors, or altering the pH of bodily fluids. For example, antacids neutralize gastric acid, thereby providing relief from heartburn and indigestion. Other basic drugs may inhibit specific enzymes or receptors, leading to a desired therapeutic effect.

Pharmacodynamics

The pharmacodynamics of basic drugs can vary widely. Antacids increase gastric pH, which reduces the corrosive effects of acid on the gastric mucosa. Antihistamines block H1 receptors, which helps alleviate allergic symptoms. Overall, the effects depend on the specific drug class and its intended therapeutic use.

Pharmacokinetics

The pharmacokinetics of basic drugs also vary. Antacids are typically rapidly absorbed and act quickly to neutralize stomach acid. On the other hand, antihistamines may have variable absorption rates and half-lives, influencing their duration of action. Distribution, metabolism, and excretion also differ among various basic drugs, which can affect dosing and efficacy.

Pregnancy

Consult a healthcare provider for safety information regarding use during pregnancy.

Breast-feeding

Consult a healthcare provider for safety information regarding use during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight.

Dosage

Children: Refer to specific guidelines or literature for dosing information.

Adults: Refer to specific guidelines or literature for dosing information.

Pregnancy

Consult healthcare professionals before use. Safety during pregnancy is not well established.

Breast-feeding

Consult healthcare professionals before use. Safety during breastfeeding is not well established.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Constipation
• Dietary fiber supplementation
• Irritable bowel syndrome
• Diverticular disease
• Weight management

Dosage

Children: Refer to appropriate guidelines for specific dosage; generally taken with adequate fluid intake.

Adults: Refer to appropriate guidelines for specific dosage; generally taken with adequate fluid intake.

Mechanism of action

Cellulose acts primarily as a bulk-forming laxative. It absorbs water in the intestines, which increases stool bulk and stimulates peristalsis, thus facilitating bowel movements. Additionally, cellulose is not digestible by human enzymes, leading to fermentation by gut bacteria, which may enhance gut health and alter gut microbiota composition.

Pharmacodynamics

Cellulose increases stool weight and frequency of bowel movements. It works by retaining water in the intestines, leading to softer stools and improved passage through the gastrointestinal tract. The bulking effect of cellulose can help alleviate constipation and promote overall digestive health. It may also play a role in cholesterol reduction and glycemic control through its effects on digestion and absorption of nutrients.

Pharmacokinetics

Cellulose is not absorbed into the bloodstream due to its indigestible nature. Instead, it passes through the gastrointestinal tract, where it adds bulk to the stool. Its fermentation by colonic bacteria produces short-chain fatty acids, which may have beneficial effects on colon health. The onset of action for cellulose as a laxative can vary but is generally within 24 to 72 hours after ingestion.

Adverse effects

• Bloating
• Flatulence
• Diarrhea
• Abdominal discomfort

Precautions

• Use with caution in patients with a history of gastrointestinal disorders.
• Monitor for potential allergic reactions in sensitive individuals.

Pregnancy

Cellulose is generally considered safe during pregnancy as it is a non-toxic, indigestible fiber.

Breast-feeding

Cellulose is also considered safe during breastfeeding; it is excreted in breast milk in negligible amounts.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Powder
• Capsules
• Tablets
• Granules

Indications

• Protection of drugs from degradation
• Taste masking
• Controlled release of active ingredients
• Improvement of patient compliance
• Targeted delivery of medications

Dosage

Children: Refer to specific product labeling for dosing information, as this varies widely based on formulation and indication.

Adults: Refer to specific product labeling for dosing information, as this varies widely based on formulation and indication.

Mechanism of action

The mechanism of action of coatings primarily involves the modification of drug release profiles. By altering the solubility and permeability of the drug through the coating material, the release rate can be controlled. For example, enteric coatings prevent drug dissolution in the acidic environment of the stomach, allowing the drug to be released in the more neutral pH of the intestine.

Pharmacodynamics

Pharmacodynamics of coated formulations can vary significantly based on the type of coating used. Immediate-release coatings dissolve quickly, leading to rapid absorption and onset of action. Controlled-release coatings are designed to dissolve slowly over time, providing a sustained release of the drug, which can lead to prolonged therapeutic effects and reduced dosing frequency. The choice of coating material and thickness influences the overall pharmacodynamic profile of the drug.

Pharmacokinetics

The pharmacokinetics of coated drugs are influenced by the coating material and the drug itself. Factors such as the rate of dissolution, absorption site, and first-pass metabolism play critical roles. Coatings can alter the bioavailability and distribution of the drug. For example, enteric coatings can enhance the absorption of drugs that are unstable in acidic conditions, potentially increasing their bioavailability when the drug reaches the intestine.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised as it is not known whether it passes into breast milk.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Indications

• Hypovolemic shock
• Severe burns
• Postoperative fluid replacement
• Sepsis
• Trauma management

Dosage

Children: Refer to established guidelines for specific dosing, as it varies based on the type of colloidal solution used and the clinical condition being treated.

Adults: Refer to established guidelines for specific dosing, as it varies based on the type of colloidal solution used and the clinical condition being treated.

Mechanism of action

Colloidal solutions work by maintaining oncotic pressure in the blood, thus helping to retain fluid within the vascular system. This is primarily due to the large molecular weight of the colloidal particles, which cannot easily pass through capillary walls. The presence of colloids in the blood helps to draw water into the circulation, increasing blood volume and improving tissue perfusion.

Pharmacodynamics

The pharmacodynamics of colloidal solutions are centered on their ability to exert osmotic pressure, which helps maintain blood volume and pressure. This effect is particularly important in conditions such as hypovolemia and shock, where fluid replacement is necessary to restore hemodynamic stability. The efficacy of colloidal solutions can vary depending on the type of colloid used, as well as the underlying clinical condition being treated.

Pharmacokinetics

Colloidal solutions are typically administered intravenously and their pharmacokinetics can vary based on the specific formulation. Generally, colloids are distributed throughout the vascular compartment and have a longer duration of action compared to crystalloids, as they remain in circulation longer. The elimination of colloids is primarily through the reticuloendothelial system, where they are metabolized or eliminated by the liver and spleen. Factors such as particle size and composition can influence their distribution and clearance.

Adverse effects

• Allergic reactions
• Injection site reactions
• Nausea
• Vomiting
• Headache
• Fever

Precautions

• Use with caution in patients with known allergies to any component of the formulation
• Monitor for signs of hypersensitivity during administration
• Consider volume overload in patients with cardiac or renal impairment

Pregnancy

The safety of colloidal solutions during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether colloidal solutions are excreted in human milk. Caution should be exercised when administering to breastfeeding mothers.

Storage

Store at room temperature, protect from light, and do not freeze. Keep out of reach of children.

Formulations

• Colloidal silver
• Colloidal gold
• Colloidal iron
• Other metal colloids

Indications

• Used as an excipient in solid dosage forms
• Facilitates drug disintegration and dissolution

Dosage

Children: Refer to specific product formulation guidelines as crospovidone is used as an excipient and does not have a direct dosage.

Adults: Refer to specific product formulation guidelines as crospovidone is used as an excipient and does not have a direct dosage.

Mechanism of action

Crospovidone acts by rapidly absorbing water and swelling upon contact with moisture. This action leads to the disintegration of solid dosage forms, thus increasing the surface area of the active ingredients and promoting their dissolution and subsequent absorption in the gastrointestinal tract. It does not affect the pH of the formulation, ensuring that the active ingredients remain stable.

Pharmacodynamics

Crospovidone exhibits properties that enhance the bioavailability of active ingredients in pharmaceutical formulations. Its ability to rapidly disintegrate tablets and capsules leads to quicker release and absorption of the drug into systemic circulation. As a disintegrant, it aids in the effective delivery of drugs that may otherwise be poorly soluble.

Pharmacokinetics

Crospovidone itself is not absorbed systemically when administered orally. It remains in the gastrointestinal tract, where it performs its function as a disintegrant. The pharmacokinetic profile of drugs formulated with crospovidone may be influenced by the enhanced dissolution and absorption rates provided by this excipient.

Pregnancy

Crospovidone is considered to have low toxicity and is generally regarded as safe for use during pregnancy, but specific studies are limited.

Breast-feeding

There is insufficient data on the excretion of crospovidone in human milk, but it is deemed safe for use during breastfeeding.

Storage

Store in a cool, dry place away from light and moisture, in tightly closed containers.

Formulations

• Powder
• Tablets

Indications

• Chronic kidney disease in patients with type 2 diabetes mellitus
• Diabetic nephropathy
• Cardiovascular protection in patients with diabetic kidney disease

Dosage

Children: Refer to BNF for Children for specific paediatric dosing recommendations.

Adults: Refer to BNF for specific dosing guidance based on the condition being treated.

Mechanism of action

Finerenone selectively inhibits the mineralocorticoid receptor (MR) in the kidney, heart, and vasculature. By blocking aldosterone's actions, finerenone reduces sodium reabsorption, lowers blood pressure, and mitigates inflammation and fibrosis in renal tissues. This mechanism leads to decreased albuminuria and preserved kidney function as well as improved cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes.

Pharmacodynamics

Finerenone shows a high affinity for the mineralocorticoid receptor, which results in effective blockade of aldosterone's actions. The drug has been found to significantly reduce levels of urinary albumin, indicating a protective effect on the kidneys. Additionally, finerenone has been associated with beneficial cardiovascular effects, including reductions in heart failure hospitalizations and improved left ventricular function.

Pharmacokinetics

Finerenone is well absorbed following oral administration, with peak plasma concentrations reached within 1 to 2 hours. It has a high volume of distribution and is extensively metabolized in the liver, primarily by CYP3A4. The elimination half-life is approximately 12 to 24 hours, allowing for once-daily dosing. Renal and hepatic impairment can affect the pharmacokinetics of finerenone, necessitating caution and adjustment in specific populations.

Interactions

• cobicistat: Severe (increases exposure)
• dabrafenib: Severe (decreases exposure)
• bosentan: Severe (decreases exposure)
• idelalisib: Severe (increases exposure)
• clarithromycin: Severe (increases exposure)
• St John's Wort: Severe (decreases exposure)
• rifampicin: Severe (decreases exposure)
• dronedarone: Unknown (increases exposure)
• antifungals, azoles: Unknown (increases exposure)
• crizotinib: Unknown (increases exposure)

Indications

• Ophthalmic solutions
• Topical formulations
• Oral solid dosage forms
• Stabilizer in various pharmaceutical preparations

Dosage

Children: Refer to specific product guidelines for dosing information, as it can vary based on formulation and intended use.

Adults: Refer to specific product guidelines for dosing information, as it can vary based on formulation and intended use.

Mechanism of action

Hydroxypropylcellulose functions primarily as a viscosity-increasing agent. When dissolved in water, it forms a gel-like consistency that helps to stabilize formulations. Its mechanism is related to its ability to create a hydrated film, which can enhance the retention of active ingredients and improve the delivery of medications to the targeted area, particularly in ocular applications.

Pharmacodynamics

The pharmacodynamic properties of hydroxypropylcellulose are primarily related to its physical characteristics rather than specific receptor interactions. It exhibits properties such as gel formation and moisture retention, which can enhance the stability and effectiveness of drug formulations. Its viscosity can influence the release rates of active pharmaceutical ingredients, thereby affecting the overall therapeutic effect.

Pharmacokinetics

Hydroxypropylcellulose is not systemically absorbed when used in pharmaceutical applications, as it acts locally at the site of application. Its pharmacokinetics involves dissolution and gel formation in the presence of water, with no significant metabolic pathways or excretion processes, given its large molecular structure. The duration of action is primarily influenced by the formulation and the concentration used.

Pregnancy

Hydroxypropylcellulose is generally considered safe for use during pregnancy as it is not systemically absorbed. However, it should be used only when clearly needed.

Breast-feeding

Hydroxypropylcellulose is not absorbed systemically and is considered safe for use during breastfeeding.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Formulations

• Ophthalmic solutions
• Topical gels
• Oral capsules
• Powders for reconstitution

Indications

• Pain management
• Inflammatory conditions
• Neurological disorders
• Cancer treatment
• Chronic diseases

Dosage

Children: Refer to specific guidelines or professional references for detailed dosing information.

Adults: Refer to specific guidelines or professional references for detailed dosing information.

Mechanism of action

The mechanism of action for lowsubstituted drugs typically involves modulation of specific receptor sites, enzymes, or ion channels in the body. This action can lead to alterations in neurotransmitter release, ion transport, or cellular signaling pathways, ultimately resulting in therapeutic effects. The specific pathways can vary based on the individual drug within this class.

Pharmacodynamics

Pharmacodynamics of lowsubstituted compounds generally involves the interaction with biological targets to elicit a pharmacological response. This can include agonistic or antagonistic effects on receptors, modulation of enzyme activity, or alteration of cellular signaling cascades. The efficacy and potency of these drugs can be influenced by their chemical structure, receptor affinity, and the physiological context in which they are used.

Pharmacokinetics

Pharmacokinetics of lowsubstituted drugs includes absorption, distribution, metabolism, and excretion (ADME) characteristics that define their behavior in the body. Typically, these drugs may have varying bioavailability based on their chemical properties, with factors such as solubility impacting absorption rates. Distribution can be influenced by protein binding and tissue permeability, while metabolism may involve hepatic pathways or phase I and II reactions. Excretion is commonly renal or biliary, depending on the drug's characteristics.

Pregnancy

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult relevant guidelines and medical advice.

Breast-feeding

It is advisable to avoid use during breastfeeding unless the benefits outweigh the risks. Consult a healthcare professional for guidance.

Storage

Store in a cool, dry place away from direct light. Keep out of reach of children.

Indications

• Used as an excipient in tablet formulations
• Used as a bulking agent in capsule formulations
• Used in food products as a thickener or stabilizer

Dosage

Children: Refer to specific product guidelines as dosage will depend on the formulation and the active ingredients.

Adults: Refer to specific product guidelines as dosage will depend on the formulation and the active ingredients.

Mechanism of action

Microcrystalline cellulose acts as a non-digestible filler that enhances the flow properties of powders during the manufacturing of tablets and capsules. It does not have a direct pharmacological action on the body but ensures that the active ingredients are effectively delivered to the patient.

Pharmacodynamics

As a non-active ingredient, microcrystalline cellulose does not exert pharmacodynamic effects typical of active pharmaceutical ingredients. Its primary role is to provide a stable and consistent matrix for the drug, facilitating the release of the active compound once ingested.

Pharmacokinetics

Microcrystalline cellulose is not absorbed in the gastrointestinal tract; it passes through the digestive system largely unchanged. It adds bulk to the stool, which may aid in promoting regular bowel movements. The substance is excreted in feces, where it contributes to dietary fiber intake.

Pregnancy

Data regarding the use of microcrystalline cellulose during pregnancy is limited. It is advisable to consult with healthcare professionals before use.

Breast-feeding

Microcrystalline cellulose is considered safe during breastfeeding, as it is not absorbed systemically.

Storage

Store in a cool, dry place away from direct sunlight and moisture.

Indications

• Used in agriculture to regulate plant growth
• Commonly applied to cereal crops to prevent lodging
• Enhances crop yield and stability

Mechanism of action

Chlormequat chloride acts at the nicotinic receptor site of the neuromuscular junction, functioning as a depolarizing agent. This action leads to initial muscular excitation which is then followed by muscle weakness. The acute toxicity of chlormequat chloride may result in respiratory arrest, and its effects can vary by species due to differing sensitivities to depolarizing neuromuscular blockers.

Pharmacodynamics

Chlormequat chloride inhibits gibberellin biosynthesis, a key hormone in plant growth regulation, which leads to reduced cell elongation and overall dwarfing of plants. This mechanism helps enhance crop stability and yield by minimizing the risk of lodging in cereals, thus promoting a more efficient harvest.

Pharmacokinetics

The pharmacokinetics of chlormequat chloride in plants involves absorption, translocation, and metabolism within plant tissues. It is rapidly absorbed and translocated throughout the plant, with a relatively short half-life, leading to effective growth regulation while minimizing residues in harvested products.

Pregnancy

No adequate and well-controlled studies in pregnant women have been conducted. Use only if clearly needed.

Breast-feeding

It is not known whether chlormequat chloride is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store in a cool, dry place. Keep container tightly closed.

Dosage

Children: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Adults: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Mechanism of action

The mechanism of action for purified compounds varies widely depending on the specific substance. Generally, purified drugs exert their effects by interacting with specific biological targets, such as receptors, enzymes, or ion channels, leading to a desired therapeutic effect. This interaction can involve binding to receptors to activate or inhibit signaling pathways, modulating enzymatic activity, or altering physiological processes.

Pharmacodynamics

Pharmacodynamics describes the effects of a drug on the body and the relationship between drug concentration and effect. For purified drugs, this can involve dose-response relationships and the time course of their action. The purified form often enhances potency and reduces variability in response among patients, which can lead to more predictable therapeutic outcomes. The overall effect is determined by the drug's affinity for its target, the efficacy of the drug-receptor interaction, and the downstream signaling pathways activated as a result of this interaction.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of a drug. For purified substances, absorption can be more efficient due to the absence of impurities that may affect solubility or stability. Distribution may also be enhanced, leading to higher bioavailability. Metabolism can be influenced by the structure of the purified compound, as it may be metabolized more readily by liver enzymes. Excretion typically occurs through the kidneys or liver, depending on the molecular characteristics of the purified drug.

Pregnancy

Consult with a healthcare professional, as the safety of purified forms of medications during pregnancy may vary depending on the specific substance.

Breast-feeding

Consult with a healthcare professional, as the safety of purified forms of medications during breastfeeding may vary depending on the specific substance.

Storage

Store in a cool, dry place, away from light and moisture, and keep out of reach of children.

Indications

• Silicosis
• Chronic obstructive pulmonary disease (COPD)
• Lung cancer associated with silica exposure

Dosage

Adults: Silica is not administered as a drug, but rather

Mechanism of action

Silica, particularly crystalline forms like quartz and cristobalite, can induce cytotoxicity and morphological transformation in cells. The cytotoxic effects are attributed to the presence of silanol groups and trace iron on the silica surface, which can generate reactive oxygen species. These interactions lead to cellular damage and transformation, suggesting multiple molecular mechanisms underlying silica's biological effects. The activity is sensitive to the silica's surface structure and composition, indicating that the biological response is a phenomenon originating from the silica's surface characteristics.

Pharmacodynamics

Silica's pharmacodynamic effects are largely related to its cytotoxic and transforming properties, particularly in lung tissue. The inhalation of crystalline silica can lead to the activation of inflammatory pathways, oxidative stress, and apoptosis in alveolar macrophages and epithelial cells. This can result in chronic inflammation, fibrosis, and ultimately, diseases such as silicosis and lung cancer. The degree of these effects varies based on the type of silica, its crystalline structure, and the presence of surface modifications.

Pharmacokinetics

The pharmacokinetics of silica is complex as it is not absorbed systemically when inhaled or ingested. Instead, inhaled silica particles can deposit in the alveolar region of the lungs, where they may persist for long periods. The body responds to silica exposure through inflammatory processes, and macrophages attempt to phagocytize silica particles. However, the persistence of these particles can lead to chronic lung conditions. Clearance mechanisms are inefficient, leading to prolonged retention in lung tissue.

Adverse effects

• Cytotoxicity
• Morphological transformation of cells
• Respiratory issues
• Silicosis
• Lung cancer

Precautions

• Use caution in occupational settings with silica dust exposure
• Regular monitoring of lung function in exposed individuals

Pregnancy

There is insufficient data on the effects of silica on pregnancy. It is advised to minimize exposure.

Breast-feeding

Limited data available; caution is advised due to potential respiratory effects.

Storage

Store in a cool, dry place, away from moisture and incompatible materials.

Formulations

• Crystalline silica
• Amorphous silica (diatomaceous earth)
• Silica gel

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing information.

Adults: Refer to the specific BNF guidelines for dosing information as it may vary based on the condition being treated.

Mechanism of action

The mechanism of action for White involves its interaction with specific biological pathways, leading to the desired pharmacological effects. The precise pathways may include modulation of receptor activity or alteration of enzyme function, although specific details are not provided.

Pharmacodynamics

Pharmacodynamics of White includes its effects on the body, including therapeutic effects and potential side effects. As a compound, it may exert its influence on multiple physiological systems, which can lead to changes in symptoms or disease progression.

Pharmacokinetics

Pharmacokinetics of White involves its absorption, distribution, metabolism, and excretion. Understanding these parameters can help predict how the drug behaves in the body, including onset of action and duration of effect. Detailed pharmacokinetic data is not specified.

Mechanism of action

Ribociclib is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and are downstream of signaling pathways which lead to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb). Ribociclib has been shown _in vitro_ to decrease pRb phosphorylation, resulting in arrest in the G1 phase of the cell cycle and reduced proliferation in breast cancer-derived models. The inhibition of pRb phosphorylation is correlated with a decrease in the volume of tumor cells.

Pharmacodynamics

Ribociclib causes concentration-dependent changes in QTcF interval. It should be used with caution in patients undergoing treatment with other QTc-prolonging agents, or in patients pre-disposed to the development of Torsades de Pointes (TdP) (e.g. those with long QT syndrome, LQTS).

Mechanism of action

Chlormequat chloride has been reported in the literature to act at the nicotinic receptor site of the neuromuscular junction. The test material may act as a depolarizing agent at this site, leading to muscular excitation followed by muscle weakness. Acute toxicity may lead to respiratory arrest. Acute toxicity of chlormequat chloride has also been reported to differ by species, which is likely due to sensitivity to depolarizing neuromuscular blockers.

Mechanism of action

...Some quartz and cristobalite dusts (crystalline) as well as the diatomaceous earths (amorphous), but not the pyrogenic amorphous silica, were cytotoxic and induced morphological transformation of SHE cells in a concentration-dependent manner. The ranking in cytotoxicity was different from that in transforming potency, suggesting two separate molecular mechanisms for the two effects. The cytotoxic and transforming potencies were different from one dust to another, even among the same structural silicas. The type of crystalline structure (quartz vs cristobalite) and the crystalline vs biogenic amorphous form did not correlate with cytotoxic or transforming potency of silica dusts. Comparison of cellular effects induced by original and surface modified samples revealed that several surface functionalities modulate cytotoxic and transforming potencies. The cytotoxic effects appeared to be related to the distribution and abundance of silanol groups and to the presence of trace amounts of iron on the silica surface. Silica particles with fractured surfaces and/or iron-active sites, able to generate reactive oxygen species, induced SHE cell transformation. The results show that the activity of silica at the cellular level is sensitive to the composition and structure of surface functionalities and confirm that the biological response to silica is a surface originated phenomenon. In vivo exposure of rat lungs to crystalline silica either by intratracheal instillation or by inhalation results in an increase in mRNA levels for inducible nitric oxide synthase (iNOS) in bronchoalveolar lavage cells (BALC), elevated nitric oxide (.NO) production by BALC, and an increase in .NO-dependent chemiluminescence (CL) from alveolar macrophages (AM). Induction of iNOS message occurs in both AM and polymorphonuclear leukocytes (PMN) harvested from silica-exposed lungs but is not significantly elevated in lavaged lung tissue. This review presents characteristics of simple and complicated coal workers' pneumoconiosis (CWP) as well as pathologic indices of acute and chronic silicosis by summarizing results of in vitro, animal, and human investigations. These results support four basic mechanisms in the etiology of CWP and silicosis: a) direct cytotoxicity of coal dust or silica, resulting in lung cell damage, release of lipases and proteases, and eventual lung scarring; b) activation of oxidant production by pulmonary phagocytes, which overwhelms the antioxidant defenses and leads to lipid peroxidation, protein nitrosation, cell injury, and lung scarring; c) activation of mediator release from alveolar macrophages and epithelial cells, which leads to recruitment of polymorphonuclear leukocytes and macrophages, resulting in the production of proinflammatory cytokines and reactive species and in further lung injury and scarring; d) secretion of growth factors from alveolar macrophages and epithelial cells, stimulating fibroblast proliferation and eventual scarring. Results of in vitro and animal studies provide a basis for proposing these mechanisms for the initiation and progression of pneumoconiosis. Data obtained from exposed workers lend support to these mechanisms. /The authors/ reported previously that freshly fractured silica (FFSi) induces activator protein-1 (AP-1) activation through extracellular signal-regulated protein kinases (ERKs) and p38 kinase pathways. In the present study, the biologic activities of FFSi and aged silica (ASi) were compared by measuring their effects on the AP-1 activation and phosphorylation of ERKs and p38 kinase. The roles of reactive oxygen species (ROS) in this silica-induced AP-1 activation were also investigated. FFSi-induced AP-1 activation was four times higher than that of ASi in JB6 cells. FFSi also caused greater phosphorylation of ERKs and p38 kinase than ASi. FFSi generated more ROS than ASi when incubated with the cells as measured by electron spin resonance (ESR). Studies using ROS-sensitive dyes and